Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The "Global Guillain-Barré Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The Guillain-Barr syndrome treatment market will register a CAGR of more than 5% by 2023.
The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barr syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barr syndrome.
Immunoglobulins are the first line treatment of Guillain-Barr syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barr syndrome treatment market during the forecast period.
Currently there is no cure for Guillain-Barr syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barr syndrome.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including CSL and Grifols the competitive environment is quite intense. Factors such as the recent approvals of immunoglobulins and strategic alliances, will provide considerable growth opportunities to Guillain-Barr syndrome treatment manufactures.
With the presence of a considerable number of companies, this market appears to be fragmented. The market will witness the emergence of many international and regional GBS treatment companies who offer therapeutics such as immunoglobulins and other therapeutics. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barr syndrome, which is expected to enhance the R&D activities of new drugs for the management of GB syndrome.
Key Players
- CSL
- Grifols
- Octapharma
- Shire
- Kedrion
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Immunoglobulins - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- CSL
- Grifols
- Kedrion
- Octapharma
- Shire
For more information about this report visit https://www.researchandmarkets.com/research/dj79s4/guillainbarr?w=12